Internal Medicine, Rheumatology · Du Bois, PA
NPI
1659438562
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
621 S Main St
Du Bois, PA, 15801
Phone (814) 371-2197
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
415 services
Medicare patients, 2024
222
Average age 73
Drug cost, 2024
$6.6M
5,536 prescriptions
Company payments, 2025
$257
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David G Stainbrook Jr. was code 99214 (office e&m - established), 142 times for 110 patients. In total David G Stainbrook Jr. billed 415 services in 10 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 142 | 110 | $66.17 | $9,396 |
| 99215 Office E&M - Established | Facility | 118 | 88 | $102.43 | $12K |
| 99213 Office E&M - Established | Facility | 78 | 66 | $40.69 | $3,173 |
| 99204 Office E&M - New | Facility | 28 | 28 | $83.56 | $2,340 |
| 99212 Office E&M - Established | Facility | 12 | 11 | $17.87 | $214 |
By year: 2022 $62K for 890 services; 2023 $57K for 718 services; 2024 $30K for 415 services.
Medicare prescription drug claims, 2024
In 2024, the drug David G Stainbrook Jr. prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 1,054 prescriptions and refills. In total David G Stainbrook Jr. wrote 5,536 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 1,054 | 2,109 | 225 | $22K |
| Prednisone Generic | 716 | 1,258 | 218 | $4,762 |
| Hydroxychloroquine Sulfate Generic | 500 | 1,031 | 112 | $18K |
| Allopurinol Generic | 396 | 961 | 106 | $3,074 |
| Humira(Cf) Pen Adalimumab | 322 | 346 | 38 | $3.2M |
| Sulindac Generic | 171 | 316 | 54 | $3,876 |
| Celecoxib Generic | 146 | 286 | 54 | $12K |
| Colchicine Generic | 140 | 291 | 52 | $12K |
| Mycophenolate Mofetil Generic | 134 | 262 | 31 | $7,695 |
| Sulfasalazine Dr Sulfasalazine | 115 | 254 | 28 | $2,643 |
| Potassium Chloride Generic | 109 | 165 | 31 | $1,516 |
| Folic Acid Generic | 101 | 213 | 28 | $1,161 |
| Enbrel Mini Etanercept | 99 | 106 | 12 | $805K |
| Benlysta Belimumab | 93 | 100 | Under 11 | $496K |
| Pilocarpine Hcl Generic | 82 | 145 | 25 | $8,548 |
Brand drugs: 1,011 claims; generic drugs: 4,512 claims; opioid claims: 74.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David G Stainbrook Jr. $257 ($257 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $257.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 17 | $257 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.